Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2010-03-03 Regulatory Filings
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
4SC to Present at the Credit Suisse Global Healthcare One-on-One Conference and the Kempen & Co Life Sciences Conference
Regulatory Filings Classification · 100% confidence The document is a short corporate news release dated March 3, 2010, announcing that 4SC AG management will be presenting at two upcoming investor conferences (Credit Suisse Global Healthcare One-on-One Conference and Kempen & Co Life Sciences Conference). It details the dates, locations, and presenters for these events. This type of announcement, which informs investors about management's schedule for engaging with the market, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, CAP, SHA). It is a general corporate update related to investor relations activities. Since it is not a specific regulatory filing type listed, and it is an announcement about future events rather than a report itself, the most appropriate classification is 'Regulatory Filings' (RNS) as a general miscellaneous corporate announcement, although 'Investor Presentation' (IP) might seem related, this document is an announcement *about* presentations, not the presentation material itself. Given the options, RNS serves as the best general regulatory/corporate news fallback for scheduling announcements.
2010-03-03 English
4SC Announces Treatment of First Patient in a Phase I Study of 4SC-205
Regulatory Filings Classification · 100% confidence The document is a news release dated February 11, 2010, announcing that 4SC AG has treated the first patient in a Phase I study for its drug candidate 4SC-205. It details the study design ('AEGIS' study), the mechanism of action of the drug, and provides commentary from management. This type of announcement, focusing on clinical trial progress and research updates, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a detailed update on drug development progress and pipeline status, it aligns best with the Investor Presentation (IP) category, which often includes such strategic and clinical pipeline information, although it is presented as a news release. It is not a formal regulatory filing like a 10-K or IR, nor is it a transcript (CT) or a simple earnings release (ER). Given the depth of the scientific and development information, IP is the most fitting category among the choices for a detailed research update.
2010-02-11 English
4SC to Present at the 12th Annual Bio CEO and Investor Conference
Report Publication Announcement Classification · 99% confidence The document is a short press release dated February 4, 2010, announcing that the CEO of 4SC AG will present an update on the company's strategy, programs, and prospects at the '12th Annual Bio CEO and Investor Conference'. This is not a full financial report (like 10-K or IR), nor is it a formal earnings release (ER) detailing results. It is an announcement about the company's participation in an investor event, which often falls under general investor relations communication. Since it is an announcement about an upcoming presentation to investors, the most fitting category is Investor Presentation (IP), although the document itself is an announcement *about* a presentation, not the presentation slides. However, given the options, this type of forward-looking update shared with investors is closely related to investor presentations. If it were purely a notice of a future report, RPA would apply, but this is a notice of a presentation/update at a conference. Given the context of presenting strategy and prospects to investors, IP is the closest fit for the *subject matter*, but due to the 'Menu vs Meal' rule and the short length (3485 chars) acting as a notice, it could also be RNS if it doesn't fit elsewhere. Since it is a specific announcement about an investor event update, and not a general regulatory filing, I will classify it as an Investor Presentation (IP) as the core topic is investor-facing strategy updates, but acknowledge the ambiguity. Re-evaluating: The document is an announcement of a presentation, not the presentation itself. It is a corporate news item distributed via DGAP. It does not fit ER, IR, 10-K, or AR. It is not a dividend (DIV), director dealing (DIRS), or capital change (CAP). It is a general corporate update aimed at investors regarding future events. This type of announcement is often categorized under Regulatory Filings (RNS) if it doesn't fit a more specific category like RPA (which is usually for announcing the *release* of a formal report). Since it's a specific event announcement, RNS is the safest fallback for non-standard corporate news.
2010-02-04 English
4SC Announces Start of Dosing in First-in-Man Phase I Study with 4SC-203
Regulatory Filings Classification · 99% confidence The document is a press release dated January 21, 2010, announcing a corporate update regarding the start of dosing in a Phase I clinical study for a drug candidate (4SC-203). It details research progress, trial design (safety, tolerability, pharmacokinetics), and provides background on the disease (AML) and the company's pipeline. This type of announcement, focusing on operational or research milestones rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), typically falls under general regulatory news or investor relations updates. Since it is a specific announcement disseminated via a news service (DGAP) and does not fit the definitions for financial reports (10-K, IR, ER, MRQ), capital changes (CAP, SHA), or specific governance/shareholder events (AGM-R, DEF 14A), the most appropriate classification is Regulatory Filings (RNS) as a general corporate news release, or potentially Investor Presentation (IP) if it were structured as a slide deck, but here it reads like a standard news update. Given the options, RNS serves as the best fit for a non-financial, non-governance, non-transactional corporate update disseminated broadly.
2010-01-21 English
4SC Announces First Patient Treated in a Phase II Hodgkin's Lymphoma Study with HDAC Inhibitor Resminostat (4SC-201)
Regulatory Filings Classification · 100% confidence The document is dated January 12, 2010, and is titled '4SC Announces First Patient Treated in a Phase II Hodgkin’s Lymphoma Study with HDAC Inhibitor Resminostat (4SC-201)'. It details the initiation of a clinical trial (Phase II study) for a drug candidate. This type of announcement, focusing on research progress, clinical trial milestones, and drug development updates, is typically classified as a general corporate news release or an update on research/development activities. Since there is no specific category for 'Clinical Trial Update' or 'Research News', and the content is a direct announcement of operational progress rather than a formal financial report (like 10-K, IR, ER) or a specific regulatory filing (like DIRS, DIV), it best fits the general 'Regulatory Filings' (RNS) category as a catch-all for significant, non-standardized corporate news, or potentially 'LTR' if it were a legal update, but here it is clearly R&D focused. Given the options, RNS serves as the most appropriate fallback for a significant corporate announcement that isn't a standard financial report or management change.
2010-01-12 English
4SC Announces Clinical Advancements in its Oncology Pipeline
Regulatory Filings Classification · 99% confidence The document is a news release dated December 22, 2009, titled "4SC Announces Clinical Advancements in its Oncology Pipeline." It details progress in initiating three new clinical trials (Phase I and Phase II) for oncology drug candidates. This content is a direct announcement of operational and research progress, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a specific update on research and development activities, it fits best under the general category of Regulatory Filings (RNS) as a miscellaneous corporate announcement, or potentially a specialized Investor Presentation (IP) if it were structured as slides, but given the format (news release distributed by DGAP), RNS is the most appropriate fallback for a specific operational update that doesn't match the other defined categories like M&A (TAR) or Capital Change (CAP). It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (10-K, IR).
2009-12-22 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.